Columbia Institute Of Sleep Medicines Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 16 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -222.61%
(FY 2023)
- Ebitda -755.18%
(FY 2023)
- Net Worth -25.47%
(FY 2023)
- Total Assets -14.89%
(FY 2023)
About Columbia Institute Of Sleep Medicines
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sharad Sharma and Kirti Sharma serve as directors at the Company.
- CIN/LLPIN
U85110DL2008PTC174537
- Company No.
174537
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Columbia Institute Of Sleep Medicines Private Limited offer?
Columbia Institute Of Sleep Medicines Private Limited offers a wide range of products and services, including CPAP, BiPAP Machine & Accessories, CPAP Machine.
Who are the key members and board of directors at Columbia Institute Of Sleep Medicines?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sharad Sharma  | Director | 11-Jul-2008 | Current |
| Kirti Sharma | Director | 03-Jul-2009 | Current |
Financial Performance and Corporate Structure Insights of Columbia Institute Of Sleep Medicines.
Columbia Institute Of Sleep Medicines Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 222.61% decrease in profit. The company's net worth observed a substantial decline by a decrease of 25.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Columbia Institute Of Sleep Medicines?
Unlock access to Columbia Institute Of Sleep Medicines's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Columbia Institute Of Sleep Medicines?
Unlock and access historical data on people associated with Columbia Institute Of Sleep Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Columbia Institute Of Sleep Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Columbia Institute Of Sleep Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
